OTC Drug Prices Compared Across Europe

22 September 1996

The average price of stomach remedies in the UK rose 8% in 1995, due largely to the introduction of H2 antagonists as antacids, according to OTCpricelink, a comparative analysis of pricing in 30 over-the-counter categories across Europe, produced by IMS SelfMedication International. The entry of the H2 brands at a higher price level enabled products already on the market to raise their prices moderately, says the study, which also notes that UK volume sales in the category fell 3% last year.

In Germany, where H2 antagonists have not yet been switched, the market grew 17% by volume and the average price per pack rose 2%. In Italy, volume sales grew 10% and average prices per pack rose 2%.

In the multivitamin market, 1995 volume sales fell 8% in Germany and 7% in the Netherlands, while average pack prices rose 1% and 6% respectively, reflecting the trend towards trading up to larger packs. This was also noted in the UK, where the average price rise per pack was 7% against volume growth of only 1%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight